Bristol-Myers Squibb Company (NYSE:BMY) discovers, develops, licenses, manufactures, markets, distributes and sells ...

Medicare’s drug pricing negotiations — the first of their kind in the United States, passed under President Joe Biden — face ...

The stock's fall snapped a two-day winning streak.

Bristol Myers Squibb Co. closed $4.40 below its 52-week high ($61.08), which the company achieved on November 11th.

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company is, we ...

The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's ...

Scientists have characterized the role of thousands of mutations in the BRCA2 cancer gene, findings that may help reassure ...

This double-digit growth in new drug sales showcases the company's ability to successfully commercialize cutting-edge ...

First Hawaiian Bank raised its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 3.5% during the 4th quarter, ...

International Assets Investment Management LLC cut its position in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 98.4% ...

In a report released yesterday, Srikripa Devarakonda from Truist Financial maintained a Buy rating on Bristol-Myers Squibb (BMY – Research ...